雅虎香港 搜尋

登入

搜尋結果

  1. 4.300
    加入追蹤清單
    +0.030 (+0.70%)
    收市時間: 2024年5月30日, 週四 下午 4:08 HKT · (HKD)。延遲價格。市場已收市。
    全螢幕顯示
    • 前收市價
      4.270
      開市
      4.290
      買盤
      4.280
      賣出價
      4.300
    • 今日波幅
      4.220 - 4.330
      52週波幅
      4.030 - 8.380
      成交量
      2.96M
      平均成交量
      3.71M
    • 市值
      8.57B
      Beta值 (5年，每月)
      1.10
      市盈率 (最近12個月)
      不適用
      每股盈利 (最近12個月)
      -0.400
    • 業績公佈日
      2024-08-27
      遠期股息及收益率
      不適用 & 不適用
      除息日
      不適用
      1年預測目標價
      7.98

    查看更多9969.HK

    相關股票

    查看全部

  2. www.remegen.cn荣昌生物制药（烟台）股份有限公司_荣昌生物 - RemeGen簡

    荣昌生物：09995.HK 港交所公告 公告及通告 业绩报告 上市文件 07 2024.05 月報表 截至二零二四年四月三十日止月份之股份發行人的證券變動月報表 26 2024.04 [海外監管公告-其他] 海外監管公告 - 華泰聯合證券有限責任公司關於榮昌生物製藥（煙台）股份有限 ...

  3. www.remegen.cn › uploadfile › 2022/04/16A2112079-E-RemeGen 1..2

    This announcement is made by RemeGen Co., Ltd.* ( ) (the. 司. ‘‘Company ’’) on a voluntary basis. Reference is made to the announcements of the Company dated February 3, 2021 and March 23, 2021 (the ‘‘Announcements ’’), and the circular dated March 5, 2021 (the Circular ’’), in relation to the adoption of the First H ...

  4. www.remegen.cn › uploadfile › 2022/04/16RemeGen Co., Ltd.* 榮昌生物製藥（煙台）股份有限公司

    Clearing HK and deposited into CCASS operated by HKSCC on June 2, 2021 and the listing of such portion of Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on June 3, 2021. It is expected that the conversion and listing of Unlisted

  5. www.remegen.cn › uploadfile › 2023/10/07A2309071-E-RemeGen 1..4

    Ms. Tam was appointed as a joint company secretary of the Company on May 11, 2020. Ms. Tam has over seven years of experience in the corporate secretarial field, and is currently serving as a manager of SWCS Corporate Services Group (Hong Kong) Limited ( 圓服集團), a professional services provider specializing in)有限公corporate services ...

  6. www.remegen.cn › uploadfile › 2024/01/23RemeGen Co., Ltd.* 榮昌生物製藥（煙台）股份有限公司

    “Share Purchase”) on the market, at a consideration from approximately HK$21.03 to HK$26.90 per H Share and a total consideration of approximately HK$12,054,900 in aggregate, pursuant to the Second H Share Award and Trust Scheme as a long-term equity incentive for employees in the

  7. www.remegen.cn › uploadfile › 2022/04/16A2112064-E-RemeGen 1..2

    Purchase’’) on the market, at a consideration from approximately HK$76.90 to HK$80.00 per Share and a total consideration of approximately HK$5,500,000 in aggregate, pursuant to the First H Share Award and Trust Scheme as a long-term equity incentive for employees

  8. www.remegen.cn › uploadfile › 2022/04/16A2203101-E-RemeGen 1..2

    For the relevant terms of the A Share Offering, please refer to the full text of the Issue Announcement of RemeGen Co., Ltd.* for the Initial Public Offering and Listing of Stocks on the STAR Market (《榮昌生物製藥(煙台)股份有限公司首次公開發行股票並在科創板上